The main way of targeted therapy for cancer genetic testing is to use targeted drugs to inhibit the activities of abnormal genes, but targeted therapy needs to be very cautious. Targeted therapy is a new type of therapeutic measure for malignant tumors, the essence of which is the use of targeted therapeutic drugs, targeted inhibition or elimination of certain important gene expression products of cancer cells, thus preventing tumor proliferation, differentiation or metastasis to a certain extent. Part of targeted therapy requires genetic testing to find out whether there are specific “targets” in tumor genes for existing drug therapy, also known as gold and silver targets. Common targeted therapy drugs include erlotinib for EGFR gene, trastuzumab for HER-2 gene, and sorafenib for multiple therapeutic targets. These drugs are strictly prohibited for self-administration, and should be administered by a physician experienced in the use of targeted therapeutic drugs, in combination with the results of genetic testing and under strict supervision of vital signs. Unauthorized use of this drug is prohibited.